1520 results about "Drug administration" patented technology

A drug administration controller has a sensor that generates a sensor signal to a physiological measurement device, which measures a physiological parameter in response. A control output responsive to the physiological parameter or a metric derived from the physiological parameter causes a drug administration device to affect the treatment of a person, such as by initiating, pausing, halting or adjusting the dosage of drugs administered to the person.

The present invention relates to a transdermal drug delivery system comprising a dermal drug delivery patch and a heating element compartment securable to the dermal drug delivery patch. A freely transferrable heating element is securable within the heating element compartment. A drug can be administered transdermally using the present invention by placing the dermal drug delivery patch upon a patient's skin at an administration site. A heating element compartment is secured to the dermal drug delivery patch and a freely transferrable heating element is placed within the heating element compartment. The heating element provides controlled heat to the dermal drug patch and the patient's skin aid thereby improves dermal drug administration.

Apparatus for drug administration is provided, including an ingestible capsule, which includes a drug, stored by the capsule, and an environmentally-sensitive mechanism, adapted to change a state thereof responsively to a disposition of the capsule within a gastrointestinal (GI) tract of a subject. The capsule further includes first and second electrodes, and a control component, adapted to facilitate passage of the drug, in response to a change of state of the environmentally-sensitive mechanism, through an epithelial layer of the GI tract by driving the first and second electrodes to apply a series of pulses at a current of less than about 5 mA, at a frequency of between about 12 Hz and about 24 Hz, and with a pulse duration of between about 0.5 milliseconds and about 3 milliseconds.

The invention relates to a medical instrument used for drug absorption of pulmonary alveoli, in particular to an intrapulmonary drug administration device atomizing drugs dissolved in liquid into fine particles reaching the pulmonary alveoli, which comprises a casing and a suction nozzle arranged at one side of the casing. The invention is characterized in that a battery, a liquid supplying bottle and an atomizer are arranged in the casing, wherein, one end of the liquid supplying bottle is communicated with the suction nozzle, while the other end is connected with the atomizer, an air inlet is arranged on the casing above the atomizer, and an air passage is arranged on the outer surface of the liquid supplying bottle; an action switch is arranged on the casing. The invention has the advantages that the drug can be atomized into uniform particles, the particles are small, and the average diameter can reach about 1 micron, which is the best technical parameter for intrapulmonary absorption; a quantitative device arranged in the invention can control the drug administration amount; the invention can be used for drug administration of bronchioles and pulmonary alveoli.

Decision information systems, methods, and computer programs for better informing decisions to use multiple drugs in drug delivery devices, including implantable devices, for drug administration. Executable computer programs and logic embodying methods of the invention can calculate consistent multiple drug mixture amounts and drug delivery flow rates. One program accepts user input indicating a desired first drug dose rate, an initial first drug concentration, a desired second drug dose rate, an initial second drug concentration, and the reservoir size of the drug delivery device. The program method calculates a first drug amount and a second drug amount to combine in a mixture as well as a first drug true concentration in the mixture. The drugs can be mixed consistent with the physician's instructions using the program output. The first drug true concentration can be entered into a programmer device as the only drug concentration entered. Another program calculates a consistent first drug, second drug, and diluent amount to be added to a mixture for injection into a fixed flow rate, implantable drug delivery device. Methods preferably output true concentrations and dose rates for all drugs to be added and most preferably show all calculations used to arrive at the flow rate and mixture amount calculations. Yet another program receives a new desired drug dose rate for a previously filled device. The program accepts the existing mixture volume and true drug concentrations for a partially depleted device and calculates a new mixture flow rate to achieve the desired dose rate using the existing mixture. The methods can be implemented as executable computer programs in programmer devices, general purpose computers, servers, handheld computers, and personal digital assistants.

A drug administration system configured to administer a drug to a user's ear includes a housing, sized and shaped to substantially fit behind the user's ear, and configured to pump the drug in controlled amounts to the user's middle ear. A drug reservoir is disposed in the housing and includes a drug configured to treat an inner ear condition. A catheter is operatively coupled to the drug reservoir and is sized and shaped to extend from the drug administration unit into the user's middle ear.

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.

An active suture that can be used for both wound closure and the delivery of therapeutic fluids to the tissue surrounding a wound is disclosed. The active suture may include a connector designed to join a fluid source, such as a syringe or conventional IV delivery system, to an internal passageway that is embedded within a braided suture. The internal passageway may be comprised of a fine polymeric tube and is capable of conducting and emitting a fluid into at least a portion of the braided suture and surrounding tissue. The invention enables delivery of an efficacious volume of drug bearing solution on the order of milliliters per day, provides a high level of fluid delivery rate control enabling the physician to start or stop drug administration at his/her discretion, and offers a means of providing more than one type of medication that may be selected post-surgically in accord with unexpected patient symptoms that may arise.

A drug administration system includes a cradle attached about an intravenous injection port having a flange extending therefrom. The cradle supports first drug administration information in the nature of machine and human readable code, for example, barcode. A syringe including a needle includes a flange extending from the syringe. The syringe supports second drug administration information in machine and/or human readable form. A scanner module is constructed to slidably receive the flange of the cradle and syringe whereby the syringe needle is aligned with the intravenous injection port. The module may be provided with an electronic scanning system for identifying the first and second drug administration information, as well as determining the amount of the drug being administered from the syringe to the injection port by monitoring movement of the syringe plunger. The information and data may be stored within the module for uploading to a remote location.

Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and/or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic drugs for micelle encapsulation may include rapamycin, geldanamycin, and paclitaxel. Administration of these micelle compositions does not require Cremophor EL or Tween 80, avoiding serious side effects associated with these products which would previously accompany such drug administration.

An active suture that can be used for the delivery of therapeutic fluids to the tissue surrounding a wound is disclosed. The active suture may include a connector designed to join a fluid source, such as a syringe, conventional IV delivery system, or infusion pump to an internal passageway that is embedded within a braided suture. The internal passageway may be comprised of a fine polymeric tube and is capable of conducting and emitting a fluid into at least a portion of the braided suture and surrounding tissue. The invention enables delivery of an efficacious volume of drug bearing solution on the order of milliliters per day, provides a high level of fluid delivery rate control enabling the physician to start or stop drug administration at his/her discretion, and offers a means of providing more than one type of medication that may be selected post-surgically in accord with unexpected patient symptoms that may arise.

The present invention provides apparatuses and methods for marking components, supplies and kits of drug administration devices and other medical systems with quality assurance information. The invention also provides apparatuses and methods for tracking time of use of such components, supplies and kits and various apparatuses and methods for preventing use or reuse of tainted, recalled or unrecognized components, supplies and kits. Quality assurance markers (QAMs) are described which store information regarding the identity and manufacturer of disposable components, supplies and kits. The invention utilizes several QAM modalities, such as, among others, 1-D and 2-D bar codes, 1-D and 2-D symbologies, holograms, written text, radio frequency identification devices (RFIDs), integrated chip smart cards, and EEPROMs.

The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable.

The present invention provides a microneedle device having a coating, which is effective even with a low molecular weight active compound and can sustain the effect of the drug for a long period of time, and a transdermal drug administration apparatus with microneedles. The microneedle device (5) has, on a microneedle substrate (8), a plurality of microneedles (6) that can pierce the skin, wherein the surface of the microneedles (6) and/or the microneedle substrate (8) is partly or entirely coated in fixed state with a coating carrier containing polyvinyl alcohol. The polyvinyl alcohol preferably has a hydrolysis degree of 94.5 mol % or more. Furthermore, the coating carrier can contain a drug.

The present invention is directed to a device for monitoring the usage of inhaled drugs by a patient. The device includes an inhaler, a use sensor, a microprocessor, a wireless transmitter and a battery compartment. These components allow information concerning drug usage to be transmitted to health care personnel that can evaluate the data to determine whether there are changes in drug usage characteristics that are indicative of an impending acute attack. The invention includes not only the device, but also the systems and methods in which the device is employed.

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.